Skip to content

Clinical application of different doses of hydromorphone sustained-release analgesia in elderly patients undergoing lumbar fusion

Clinical application of different doses of hydromorphone sustained-release analgesia in elderly patients undergoing lumbar fusion

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064863
Enrollment
Unknown
Registered
2022-10-20
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pain

Interventions

Group A:0.02% hydromorphone hydrochloride 0.2 mg gelatin sponge was aspirated by epidural indwelling
Group B:0.02% hydromorphone hydrochloride 0.3 mg gelatin sponge was aspirated by epidural indwelling
Group C:0.02% hydromorphone hydrochloride 0.4 mg gelatin sponge was aspirated by epidural indwelling

Sponsors

Ganzhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. ASA grade I-II; 2. Patients were in good mental state and had no communication disorder, the inflammatory reaction was controlled before operation; 3. Patients and their family members voluntarily signed the informed consent; 4. No history of allergic reaction to opioids or nsaids, and no long-term use of central nervous system; 5. The basic diseases were controlled in acceptable level, no alcohol abuse, no visual or hearing impairment; 6. The range of operation was 1-2 vertebrae.

Exclusion criteria

Exclusion criteria: 1. Complicated with mental disorders and use of psychotropic drugs; 2. Preoperative CAM score >=20; 3. Long-term use of analgesic drugs; 4. Combined with immune, blood and endocrine system diseases; 5. Patients had infectious diseases before operation; 6. Severe heart, liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
Visual analogue scale (VAS) pain score;Serum levels of C-reactive protein (CPR) , interleukin-6(IL-6) and tumor necrosis factor (TNF-a) ;Patient cognitive function;

Secondary

MeasureTime frame
Adverse reaction;Hemodynamics;

Countries

China

Contacts

Public ContactDeng Ruiming

Ganzhou People's Hospital

15570115910@163.com+86 15570115910

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026